Skip to content
OpenCapital
Get started

Marker Therapeutics, Inc. MRKR Q4 2024 Annual earnings

Reported March 31, 2025 · Before market open

Revenue$2.3MBeat by $1.0M
EPS-$0.42Miss by $0.20
Revenue estimate$1.2M
EPS estimate-$0.22

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$682.1K
EPS estimate-$0.25

Versus estimates

Revenue

Q4 2025$1.1MBeat by $417.9KQ3 2025$1.2MBeat by $509.9KQ2 2025$861.2KBeat by $430.6KQ1 2025$349.1KBeat by $174.6K
Q4 2024$2.3MBeat by $1.0M

Diluted EPS

Q1 2026-$0.16Beat by $0.02Q4 2025-$0.04Beat by $0.17Q3 2025-$0.12Beat by $0.24Q2 2025-$0.29Beat by $0.01Q1 2025-$0.27Beat by $0.39
Q4 2024-$0.42Miss by $0.20

Ask the moment Marker Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Marker Therapeutics, Inc. report Q4 2024 earnings?
Marker Therapeutics, Inc. (MRKR) reported Q4 2024 earnings on March 31, 2025 before market open.
What were Marker Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Marker Therapeutics, Inc. reported revenue of $2.3M and eps of $-0.42 for Q4 2024.
Did Marker Therapeutics, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $1.2M by $1.0M. EPS missed the consensus estimate of $-0.22 by $0.20.
Where can I find Marker Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001410578-25-000549) directly on SEC EDGAR. The filing index links above go to sec.gov.